Stanford

Tamara Dunn

Clinical Associate Professor, Medicine - Hematology

CLINICAL OFFICE (PRIMARY)

- **VA Palo Alto Health Care System Dept of Hematology**

  3801 Miranda Ave

  Palo Alto, CA 94304

  Tel (650) 617-2732 **Fax** (650) 614-8473

Bio

BIO

Dr. Tamara Dunn is a clinical associate professor in the Division of Hematology at the Stanford University School of Medicine. She is a clinician with a special interest in medical education, diversity, equity, and inclusion. Specifically, she is committed to improving workforce diversity and creating inclusive workplaces. She is currently the Program Director for the Stanford Hematology/Oncology Fellowship and one of the Associate Chairs of Diversity and Inclusion for the Department of Medicine at Stanford. She is a member of the inaugural American Society of Hematology (ASH) Ambassador Cohort and serves on the ASH Women in Hematology committee, which she co-chairs. She is on the steering committee and is a mentor for Stanford's Leadership Education in Advancing Diversity (LEAD) program. She takes pride in treating underserved veterans at the Palo Alto Veterans Hospital, where she sees both classical and malignant hematology. Outside of medicine she enjoys singing, dancing, sports (Go Chiefs! Go Warriors!), board games, movies, and spending time with friends and family including her 3 young children, spouse, and energetic vizsla Casey.

CLINICAL FOCUS

- Hematology

ACADEMIC APPOINTMENTS

- Clinical Associate Professor, Medicine - Hematology

ADMINISTRATIVE APPOINTMENTS

- Associate Chair, Diversity & Inclusion, Department of Medicine, (2020- present)
- Program director, Hematology Fellowship, (2017- present)

PROFESSIONAL EDUCATION

- Board Certification: Hematology, American Board of Internal Medicine (2023)
- Fellowship: Stanford University Hematology and Oncology Fellowship (2013) CA
- Residency: Stanford University Internal Medicine Residency (2009) CA
- Medical Education: SUNY Downstate College of Medicine (2006) NY

Research & Scholarship

CLINICAL TRIALS

- Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Not Recruiting

Publications

PUBLICATIONS

- **Gender differences in question-asking at the 2019 American Society of Hematology Annual Meeting.** *Blood advances*
  Moazzam, S., Onstad, L., O'Leary, H., Marshall, A., Osunkwo, I., Du, E., Dunn, T., Dunlap, J., Reed, B., Luger, S., Lee, S. J.
  2020; 4 (21): 5473–79

- **Genomic landscape of Neutrophilic Leukemias of Ambiguous Diagnosis.** *Blood*
  Zhang, H., Wilmot, B., Bottomly, D., Dao, K. T., Stevens, E., Eide, C. A., Khanna, V., Rofelty, A., Savage, S., Reister-Schultz, A., Long, N., White, L., Carlos, et al
  2019

- **Effect of Fitbit and iPad Wearable Technology in Health-Related Quality of Life in Adolescent and Young Adult Cancer Patients.** *Journal of adolescent and young adult oncology*
  Yurkiewicz, I. R., Simon, P., Liedtke, M., Dahl, G., Dunn, T.
  2018

- **Effect of Fitbit and iPad Wearable Technology in Health-Related Quality of Life in Adolescent and Young Adult Cancer Patients** *JOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY*
  Yurkiewicz, I. R., Simon, P., Liedtke, M., Dahl, G., Dunn, T.
  2018; 7 (5): 579–83

- **A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.** *International journal of hematology*
  Dinner, S. n., Dunn, T. J., Price, E. n., Coutré, S. E., Gotlib, J. n., Berube, C. n., Kaufman, G. P., Medeiros, B. C., Liedtke, M. n.
  2018

- **Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response** *LEUKEMIA & LYMPHOMA*
  Saygin, C., Papadantonakis, N., Cassaday, R. D., Liedtke, M., Fischer, K., Dunn, T., Patel, B. J., Sobecks, R., Kalaycio, M., Sekeres, M. A., Mukherjee, S., Gerds, A. T., Hamilton, et al
  2018; 59 (2): 363–71

- **A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma.** *British journal of haematology*
  Dunn, T. J., Dinner, S., Price, E., Coutré, S. E., Gotlib, J., Hao, Y., Berube, C., Medeiros, B. C., Liedtke, M.
  2016; 173 (2): 253-259

- **Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia** *LEUKEMIA RESEARCH*
  Liedtke, M., Dunn, T., Dinner, S., Coutre, S. E., Berubea, C., Gotlib, J., Patel, S., Medeiros, B.
  2014; 38 (12): 1441-1445

- **Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia.** *Leukemia research*
  Liedtke, M., Dunn, T., Dinner, S., Coutré, S. E., Berube, C., Gotlib, J., Patel, S., Medeiros, B.
  2014; 38 (12): 1441-1445

- **Hemophagocytic lymphohistiocytosis in pregnancy: a case report and review of treatment options** *HEMATOLOGY*
  Dunn, T., Cho, M., Medeiros, B., Logan, A., Ungewickell, A., Liedtke, M.
  2012; 17 (6): 325-328